P2.06-06 Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC

Immune checkpoint blockade has revolutionized the therapeutic approach to non-small cell lung cancer (NSCLC), though not all patients benefit and some develop resistance, necessitating new approaches. The CD226 axis has emerged as a critical regulator of natural killer (NK) and T-cell anticancer responses, and comprises the immunostimulatory receptor CD226 and the immunoinhibitory checkpoints T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT), CD96, and poliovirus receptor-related immunoglobulin domain containing (PVRIG) on NK and T cells, plus their shared ligands CD155 and CD112 on cancer cells and antigen presenting cells.